Wilms' tumor gene (WT1) can play significant roles both as a tumor suppressor gene and oncogene. The role of tumor suppressor gene can be supported by the finding of leukemic cells showing WT1 mutation, as well as high levels of WT1 RNA were expressed by the 48% of patients, with a negative impact on the clinical outcome. Moreover, oncogenic role of WT1 was also evident, as wild-type WT1 gene and WT1 RNA were found to be highly expressed in the bone marrow and peripheral blood of a variety of leukemia and myelodysplastic syndromes (MDS) in comparison to normal bone marrow and progenitor cells. In acute myeloid leukemia, chronic myeloid leukemia in blast crisis and advanced cases of MDS, a high expression of WT1 has been frequently detected and elevated level of WT1 in leukemia and MDS are associated with poor prognosis, poor response to therapy and disease progression. 1 Interestingly, the presence of nuclear factor-kappa B (NF-kB)-binding sites within the WT1 promoter has been reported 2 and NF-kB activity seems to be relevant in the pathogenesis of MDS. One of the most effective compounds in the block of NF-kB activation is bortezomib, a proteasome inhibitor largely adopted for treatment of relapsed/ resistant multiple myeloma patients, effective as anti-proliferative agent in many tumor cell lines. 3 Suberoylanilide hydroxamic acid (SAHA) has been reported to potentiate apoptosis and suppress NF-kB activation. 4 Thus, also considering the putative role of NF-kB in the controlling WT1 expression, we planned to assess the effect of bortezomib (proteasome inhibitor) and vorinostat (histone deacetylase inhibitor, formerly known as suberoylanilide hydroxamic acid) on cell viability and WT1 expression in MO7-e (chosen an in vitro model for leukemia and megakaryocytes-driven chronic myeloid disorders) 5 and p39 (an in vitro model for MDS). 6 As other authors previously reported a synergistic antiproliferative effect exerted by bortezomib plus vorinostat in myeloma and leukemia cells, we also tested the effect of their combination on our cell lines.
MO7-e, a megakaryoblastic cell line (DSMZ: German Collection of Micro-organisms and cell cultures), and P39 cell Letters to the Editor line, derived from MDS-CMML patient (a kind gift by Dr E Hellströ m-Lindberg, Karolinska University, Stockholm), were grown in RPMI-1640 medium (Gibco-Life Technologies, Carlsbad, CA, USA), supplemented with 10% fetal bovine serum (FBS), 2 mmol/l L-glutamine and 1% gentamicin at 371C in a humidified atmosphere containing 5% CO 2 . Additionally, 10 ng/ ml recombinant human granulocyte macrophage colony-stimulating factor (Novartis, Basel, Switzerland) was added in MO7-e cell culture. Cells were treated with 5-50 nM of bortezomib and 0.5-5 mM of vorinostat for 24 and 48 h. Drugs were diluted in sterile water and added at the beginning of incubation.
After that, cell viability was tested by 3-[4,5]dimethylthiazol-2,5-diphenyltetrazolium bromide assay. Data from 3-[4,5]dimethylthiazol-2,5-diphenyltetrazolium bromide assays were used for the combination studies, which were performed at 24 h using IC 15 and IC 50 values of the two drugs. We calculated IC 50 values on the basis of the median effect plot:
x ¼ log (D) versus y ¼ log (f a /f u ), where D is the dose, f a is the fraction affected by dose D and f u is the unaffected fraction (1Àf a ). Then we calculated IC 15 values using the equation
1/m , where D m is IC 50 and m is the slope of the median effect plot. Drug interaction between bortezomib and vorinostat were assessed using the combination index, where combination index o1, 1, 41 indicate synergism, additive effect and antagonism, respectively. Data analysis was performed with the use of Calcusyn software (Biosoft, Oxford, UK). Quantitative reverse transcription-PCR was performed on all samples to determine the expression of WT1 on an i-Cycler iQ Apparatus (Bio-Rad, Hercules, CA, USA), as previously reported. 7 Abelson (ABL) was chosen as housekeeping gene in order to keep a stable expression between different samples and low interassays variability.
Bortezomib reduced cell viability on both MO7-e ( Figure 1a ) and P39 cell lines (Figure 2a ) in a dose-and time-dependent manner. Similar effect on cell viability was also observed when MO7-e and P39 cell lines were treated by vorinostat (Figures 1b  and 2b) . Moreover, bortezomib and vorinostat showed a synergistic effect when added in combination to MO7-e cell line (Figure 1c) . In contrast, when P39 were co-incubated with bortezomib plus vorinostat, an antagonistic effect on cell viability was observed (Figure 2c ). Bortezomib considerably reduced WT1 expression on both MO7-e and P39 cell lines (Figures 3a and 4a ) differently according to concentrations added and incubation length. Vorinostat also reduced WT1 expression on both the MO7-e and P39 cell lines (Figures 3b  and 4b ), being more effective than bortezomib on MO7-e cell line and inducing a similar reduction of transcript levels in P39 cells.
Moreover, the co-exposure of MO7-e to bortezomib plus vorinostat induced a synergistic WT1 downregulation in both cell lines (Figures 3c and 4c) .
WT1 gene has been reported to play a significant role in differentiation and leukemogenesis. In normal hematopoiesis, CD34 þ progenitors express high levels of WT1 relative to mature hematopoietic cells. In human leukemic cells HL60 and U937, differentiation induction can be blocked by the ectopic WT1 expression, and WT1 isoforms could be relevant in this phenomenon.
1 High WT1 levels in peripheral blood have been reported to be significantly correlated with the evolution of RAEB and RAEB-t to overt acute myeloid leukemia. Finally, WT1 has been enclosed in a set of few genes characterizing the transcriptome profile of CD34 þ cells purified from the peripheral blood of patients affected by idiopathic myelofibrosis.
Our results show that bortezomib and vorinostat are able to reduce the expression of one of the most relevant oncogenes involved in hematological malignancies, either when used separately or, interestingly, with a synergistic effect when coadded to our cell lines. These data are in line with those published by other authors that reported that depsipeptide, one of the most effective HDAC inhibitors, exerted a proapoptotic effect on human myeloid leukemic cell lines HL-60 and K562 where mitochondrial translocation of Bax were markedly enhanced by the proteasome inhibitor bortezomib. 8 Interestingly, recently it has been reported that 5-azacytidine, a DNA methyltransferase inhibitor, induces DNA-double-strand breaks, apoptosis and synergistic cytotoxicity with bortezomib against multiple myeloma cells. Considering the well-proven efficacy of 5-azacytidine in MDS, and results coming from our study, a combination of these two drugs in MDS patients would be promising. Nevertheless, in the absence of further data, the combinated use of bortezomib and vorinostat could be considered with caution in patients affected by high-risk MDS because of their antagonistic anti-proliferative effect observed in our P39 model.
In conclusion, if these results will be confirmed by further ex vivo studies, treatment by bortezomib in combination with vorinostat could be an interesting help in treatment of patients affected by acute leukemia or MDS showing high WT1 levels at diagnosis. Transfusion is employed in virtually every adult patient with acute leukemia and leads to immunomodulatory effects that are not yet characterized fully. 1 These effects include downregulation of Th1 immunity and reciprocal activation of Th2 immunity. 2 Thus avoiding, or reversing the effects on cellular immunity due to transfusion in patients with acute leukemia is a potential strategy for improved clinical outcomes. A growing body of data from in vitro animal and clinical studies suggests that blood transfusion has clinically relevant immunologic effects on patients, and that these effects are at least in part due to altered T-cell function. 1 The literature on the effects of transfusion on recipient immunologic function and clinical outcomes is extensive but largely restricted to surgical settings. It is not known whether similar effects occur in patients with hematologic malignancies.
S Galimberti
Infusion of ABO-mismatched platelets is associated with an increased incidence of multi-organ failure and death in stem cell transplants for acute myeloid leukemia. 3 In many centers, the approach to platelet transfusion is to give little or no priority to ABO matching of donors and recipients. One reason is that ABO mismatching of donor and recipient has little effect on clinical outcome in allogeneic stem cell transplantation. 4 We hypothesized that immune function may be important in eradicating residual disease during and after induction therapy in acute leukemia and that transfusion might alter immune function. We examined retrospectively the survival in adult patients with acute leukemia who systematically participated in different protocols for transfusion including ABO identical versus nonidentical platelets, leukoreduced versus non-leukoreduced transfusions and washed versus unwashed transfusions.
To review the association of blood transfusion practice and clinical outcomes in acute leukemia, we chose the period 1985-1994 as these years spanned a period including two randomized transfusion trials in patients with acute leukemia in our hospital, and detailed clinical information had already been collected. The medical records of 120 consecutive patients were analyzed, of whom 115 had complete records available for review. Each patient received treatment with curative intention, that is, fulldose myeloablative chemotherapy was initiated shortly after diagnosis. Most of these patients (n ¼ 83) were participants in two separate randomized trials of ABO identical versus
